Introduction
Women with germline loss of function mutations in the BRCA2 gene have a significantly increased lifetime risk of developing breast and ovarian cancers [1] .
Mutations in BRCA2 also predispose to developing cancers of the pancreas, stomach, gallbladder, bile duct, skin, and in men, the prostate [2] . Germline BRCA2 mutations are found in approximately 3% of breast and 8% of ovarian cancers, whilst BRCA2 is somatically mutated in 2% of breast and 3% of ovarian cancers [3, 4] .
BRCA2 functions as a tumour suppressor, and somatic loss of the second, wild type allele in tumours is a common event. BRCA2 encodes a protein that has a key role in the accurate repair of DNA double-strand breaks (DSBs) through the process of homologous recombination (HR) [5] . When HR is active, the homologous DNA sequence to the DNA flanking the DSB is used as a template that guides DNA synthesis on the damaged sister chromatid, resulting in high-fidelity repair. During this process, BRCA2 interacts with and ensures the loading of the DNA recombinase RAD51 onto DNA at the site of the DSB. The formation of RAD51/DNA nucleoprotein complexes facilitates strand invasion, a critical step in the repair of DSBs by HR.
When BRCA2 is defective, DSBs fail to be repaired by HR and more error-prone mechanisms of DNA repair are used [6, 7] . In some cases, the enhanced utilisation of error-prone mechanisms of DNA repair can lead to genomic instability and ultimately tumour development [reviewed in [8] ]. Consistent with its role in HR, BRCA2 deficient human tumours tend to be associated with mutations in the TP53 gene, with mutations identified in up to 60% of BRCA2 mutant breast cancers [9] and 70% of BRCA2 mutant ovarian cancers [10] . BRCA2 mutant human tumours are characterised by a particular mutational signature, namely base substitutions and an enrichment of large deletions (up to 50 bp) which have breakpoints that are flanked by regions of DNA sequence microhomology [11] [12] [13] . These latter mutations are possibly the result of error-prone homology directed DNA repair in tumour cells that have defective HR [6, 7, 14] . The HR defect in BRCA2 mutant tumours (and also BRCA1 mutant tumours) has recently been exploited in the design of a synthetic lethal treatment approach that exploits small molecule inhibitors of the DNA repair proteins Poly-(ADP-ribose) Polymerase (PARP)-1/2 (reviewed in [15] ). PARP1 is an enzyme involved in the repair of single-strand DNA breaks and inhibitors of this protein result in the stalling of replication forks. HR repairs the DNA lesions induced by PARP1 inhibitors in wild type cells, making HR defective BRCA2 mutant cells highly sensitive to these therapeutics.
Genetically engineered mouse models (GEMM) of human cancer have been used as a tool to study genetic lesions thought to promote tumour development. Many of these models recapitulate the molecular and cellular features of human cancer and have provided insights into the processes that drive tumorigenesis [16, 17] . GEMMs have also allowed investigators to test the response of novel cancer therapeutics in pre-clinical in vivo models that have predefined genetic aberrations [18] . For example, Brca2 mutant mice with mammary tumours show an anti-tumour response to PARP1/2 inhibitors [19, 20] . In addition, DNA sequence analyses of tumours from GEMMs have identified secondary mutations in cancer-promoting genes that are also mutated in human tumours [21] [22] [23] [24] . These comparative genomics approaches have shown that genes mutated in both species can promote tumour formation and provide a method for identifying cancer targets within the setting of defined genetic initiating event.
In this study we used whole exome DNA sequencing of Brca2 null, Trp53 null mammary tumours from mice to identify additional somatic mutations associated with these cancers. We compared the somatic mutations we identified in this mouse model with the genes mutated in human cancer and the mutations found in human BRCA2 mutant breast and ovarian cancers.
Materials and Methods

Generation of Brca2 null, Trp53 null mammary tumours
Mice carrying the Blg-Cre transgene [25] were mated with animals with both loxP flanked Brca2 and loxP flanked Trp53 containing alleles [26] generating Blg-Cre
Brca2
f/f Trp53 f/f animals [27] . Mammary tumour and spleen tissue from mutant animals were excised from humanely killed tumour bearing mice. Part of the tumour was fixed in 4% phosphate-buffered formalin overnight for histological analysis and immunohistochemistry and part was snap frozen on dry ice for isolation of DNA.
Genomic DNA preparation
Genomic DNA was isolated from tumours and spleens using the DNeasy Blood and
Tissue kit (Qiagen, UK), according to the manufacturer's instructions. DNA was quantified using the Qubit 2.0 kit (Life Technologies, UK).
Whole exome DNA sequencing
Three micrograms of genomic DNA was fragmented to 200 bp using a Covaris E Series instrument (Covaris Inc, MA, USA) and the resultant library subjected to DNA capture using the 50 Mb SureSelect Mouse All Exon kit (Agilent, CA, USA). DNA capture was carried out according to the manufacturer's instructions. Illumina pairedend libraries were prepared from the captured target regions and quantified using a Bioanalyzer DNA chip (Agilent), followed by sequencing on a HiSeq2000 platform (Illumina, San Diego, CA, USA), acquiring 2 × 76 bp reads. Casava software (v1.8, Illumina) was used to make base calls. Sequences were output in fastq format.
Reads failing the Illumina chastity filter were removed before further analysis. 
Read mapping and detection of somatic mutations in exome sequencing
Burrows-Wheeler Alignment (BWA, v0.5.9) was used to align reads to the mouse reference genome (GRCm37) [28] . Duplicate sequence reads (PCR-derived duplicates) were removed from further analysis at this point. Base quality recalibration, realignment around indels, and variant calling were performed using the Genome Analysis Tool Kit (GATK, v1.0-6144-gdd92a14) using the Broad best practice variant detection workflow [29] . The MuTect algorithm (v1.1.4) was also used to identify somatic single nucleotide mutations in targeted exons [30] . Small insertions and deletions detected in the tumour sample that were absent in the matched normal were considered to be candidate somatic mutations. Variants called in regions not covered by the exome capture probes and variants marked as low quality (QUAL below 20) were excluded. Candidate somatic mutations were also assessed to confirm their validity by visualizing sequencing data using the Broad
Integrative Genomics Viewer tool [31] . The PROVEAN (Protein Variation Effect Analyzer, v1.1.3) software tool was used to predict whether a mutation has an impact on the biological function of a protein.
Detection of copy number alterations in exome sequencing
Copy number alterations were predicted using exome DNA sequencing data and the CONTRA (v2.0.4) and CoNIFER (v0.2.2) software packages using default parameters [32, 33] .
Validation sequencing
To validate somatic mutations by Sanger sequencing, PCR amplicons encompassing the candidate mutation sites were sequenced in tumour and spleen DNA using standard methods. PCR primers for amplification and sequencing were designed using the UCSC In Silico PCR tool [34] .
Comparison with human somatic mutation data
The likely human orthologs of the mouse Brca2 null, Trp53 null deficient mammary tumour somatic mutations were identified using the MGI curated sets of homology (from NCBI HomoloGene build67) [35] . Tumour DNA sequence data from nonfamilial human breast cancer and ovarian cancer was accessed via the TCGA data portal [36] . 
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Results
Exome sequencing of Brca2 deficient mouse tumours
We wanted to study the pattern of genomic alterations present in Brca2 deficient tumours, and in particular, we sought to determine if functional disruption of the Metaplastic Spindle Cell Tumours (MSCTs), and one Adenomyoepithelioma (AME).
These tumours were high grade, with a high mitotic index and exhibited nuclear polymorphism (Table S1 and [27] ). Only 2/11 (18%) were estrogen receptor (ER) positive (cut-off for ER positivity >5% ER expressing cells).
DNA from Blg-Cre Brca2 f/f Trp53 f/f mammary tumours was subjected to exome capture and sequencing using a Illumina HiSeq 2000 platform. A schematic of the workflow is shown in Figure S1 . We also exome captured and sequenced DNA derived from the normal spleen of each animal. A total of 12 tumours and matched spleens were sequenced from 12 Blg-Cre Brca2 f/f Trp53 f/f animals. An average of 75 million sequencing reads was generated for each sample giving a median depth of 42x (Table S2 ). In these mouse tumour samples the most recurrently mutated genes in human breast cancer were each DNA exome sequenced at > 10x (Table S3) and Trp53 exons 2-10 when compared to the matched spleens ( Figure 1 and Table   S4 ). The relative frequency of Brca2 and Trp53 exons not flanked by loxP sites remained unchanged in all tumour/spleen comparisons ( Figure 1 and Table S4 ). This data is in agreement with our previous droplet digital PCR data that demonstrated that these tumours had fewer copies of the loxP flanked Brca2 and Trp53 exons compared to the exons outside of these regions [27] . Histologically, all samples were at least 80% tumour cells [27] .
Somatic mutations and copy number alterations in mouse Brca2 null,
Trp53 null mammary tumours
To identify somatically occurring mutations in Blg-Cre Brca2 f/f Trp53 f/f mammary tumours, we compared exome sequence data from tumour DNA and matched spleen DNA. From 12 tumour/spleen comparisons, we identified 963 candidate somatic mutations in a total of 657 genes (Table S5 and Table S6 ). There were between 41
and 129 candidate alterations in each tumour sample, a range which is comparable to the average of 60 exomic mutations identified in human breast tumours [4] ( Figure   2A and Table S7 ). 714 of these candidate mutations (74%) were base substitutions, 144 (15%) were insertions and 105 (11%) deletions ( Figure 2B and Figure 2C ). The seven IDC-NST tumours had an average of 81 candidate somatic mutations, the four
MSCTs had an average of 73 somatic mutations and the one AME tumour had 101 somatic mutations (Table S8) . Of the 963 candidate somatic mutations, 290 were predicted to cause an amino acid sequence alteration in a total of 241 genes (Table   S9) , with 22 (8%) being potential frameshift mutations, 13 (4%) nonsense mutations, 225 (78%) missense mutations and 30 (10%) splice site mutations ( Figure 2D , Figure   2E and Table S7 ). Of the 241 genes predicted to have coding mutations in the mouse mammary gland tumours, 191 likely human orthologs were identified using the Mouse Genome Informatics curated sets of homology (Table S9 ). To be confident in our exome sequence variant calling, we also assessed 14 randomly selected candidate somatic mutations using Sanger sequencing. The majority of these mutations (17/23) were confirmed by this orthogonal sequencing method, giving us some confidence in our variant detection approach (Table S10) .
We also used the exome DNA sequencing data to estimate the presence of (Table S11 ). CoNIFER identified a total of 146 candidate copy number gains and 45 candidate copy number losses ( Figure 3C ), with between 2 and 24 gains and 0 and 10 losses identified in each tumour sample ( Figure 3D and Figure 3E ) (Table S12 ). Analysis of the data output from CONTRA and CoNIFER revealed a total of 87 genes predicted to have a DNA copy number alteration by both packages (Table S13) . [39] . Each of these missense mutations was clustered within the first Iglike 1 domain ( Figure 4A ). We also noted two tumours with mutations in Prr14l, both being frameshift mutations, p.E236fs and p.D451fs, however only the latter mutation validated (Table S10 ). CD244 and PRR14L are both somatically mutated in human cancer, with CD244 mutations present in bladder cancer (3.6% of TCGA samples) and melanoma (3.6% of TCGA samples), while PRR14L is mutated in uterine cancer (6% of TCGA samples) [40] . At present, few mutations have been identified in either gene in human breast cancer (CD244 0.2% of TCGA samples; PRR14L 0.4% of TCGA samples).
Recurrent somatic mutations and copy number alterations
We also searched for recurrent somatically occurring DNA copy number alterations Figure 4A ). All of these mammary tumour mutations validated using Sanger sequencing (Table S10) Figure 4A and Figure 4D ).
Comparison of
KRAS (v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog) is frequently mutated in human cancer (57.9% TCGA pancreatic adenocarcinoma; 43% TCGA colorectal adenocarcinoma; 32.6% TCGA lung adenocarcinoma) but is only found altered at a low frequency in human breast cancer (0.8% TCGA breast cancer). Mutations at KRAS amino acid 13 are likely cancer drivers, and encode a constitutively active form of the protein [53] . As expected, PROVEAN predicted that the p.G13R mutation altered Kras protein function.
We also compared our data set to the mutational profile of human tumours with somatic BRCA2 mutations. To do this we used mutation data from the TCGA, including exome sequence data from 778 invasive breast carcinoma samples and 520 ovarian serous cystadenocarcinoma samples [3, 4] . These data included 13 BRCA2 mutated breast cancers (Table S14 and Table S15 ) and 13 BRCA2 mutated ovarian cancers (Table S16 and Table S17 ). We also included mutation data from five additional BRCA2 mutated breast samples sequenced as part of the ICGC consortium [54, 55] (Table S14 and Table S15 ).
We compared the somatic mutations we identified in Brca2 null, Trp53 null mouse mammary tumours with the genes mutated in human BRCA2-associated breast cancers. This comparison identified 31 genes mutated in both cancer types ( Figure   5A and Table S18 ). These genes included GATA3 and CD244, a recurrently mutated gene in the Brca2 null mouse model. Of these 31 genes, three genes are recurrently mutated in human BRCA2 mutant breast cancer and included genes thought to be involved in cancer development. For example, RYR2 is a member of the ryanodine receptor family, which encode proteins that form calcium channels and have been implicated in breast cancer risk and tumour grade [56, 57] . SPEN (split ends, homolog of Drosophila) an RNA-binding coregulatory protein and negative regulator of the Notch pathway was identified as a cancer associated gene in adenoid cystic carcinoma [58] , and SYNE1 encodes a spectrin repeat containing protein that localizes to the nuclear envelope and has been reported to be mutated in several cancer types [1, 2, 5]. There were 11 genes in common between the mammary tumour mutations and genes mutated in human BRCA2 mutant, TP53 mutant breast tumours ( Figure 5B and Table S18 ). A similar analysis involving a comparison of the
Blg-Cre Brca2 f/f Trp53 f/f tumour mutations with the genes mutated in human BRCA2
mutant ovarian cancers identified 16 genes, while 10 genes were also mutated in BRCA2 mutant, TP53 mutant ovarian cancers ( Figure 5C , Figure 5D and Table S19 ).
These included RYR2 and SYNE1, as well as two human tumours with mutations in
VPS13B, a gene that encodes a member of the vacuolar protein-sorting pathway previously implicated in tumorigenesis [59] [60] [61] . Of the genes mutated in both human and mouse Brca2/BRCA2 mutant tumours, RYR2, SYNE1, SPEN and VPS13B are recurrently mutated in the human disease. None of the mutations we identified in these mouse genes have reported mutations at the same position in human cancer.
Furthermore, RYR2, SYNE1, SPEN and VPS13B are all large genes (> 12 kb coding sequence), suggesting that the mutations in these genes might be due to their size rather than being selected for as driver events.
Base substitutions and microhomology
Recent whole genome sequencing studies have uncovered the patterns of mutational signatures present in human breast cancer [12] . Detailed analysis of the spectrum of mutation types revealed that tumours could be subgrouped based on these alterations, which are likely due to common exposure to mutagens or particular underlying DNA damage/repair mechanisms [13] . Breast tumours with either a BRCA1 or BRCA2 mutation display a mutation signature that clusters these cancers together, namely a relative increase in deletions at regions of DNA sequence flanked by microhomology, thought to be the result of non-homologous end joining (NHEJ) double-strand break repair, and a base substitution signature [12, 13, 62] . deletion events in total ( Figure 7A ). Of these the majority were 1 bp deletions ( Figure   7B and Figure 7C ). However, in contrast to human BRCA mutant tumours and also mouse Brca1 mutant tumours [12, 21] , the majority of deletions in Blg-Cre Brca2
Trp53 f/f mammary tumours did not exhibit flanking sequence microhomology ( Figure   7D ). [19, 65, 66] . Nevertheless, some caution should be used when directly inferring the mechanisms of resistance to therapies as the different mutational spectrum present in this model could affect the mode of 19 resistance. Despite the apparent differences in the mutational spectrum of the disease, elements of the underlying biology of mouse mammary tumours might accurately reflect the human disease. For example, even though the mutational spectrum might seem distinct, the biological processes that are driven by mutant genes in the mouse model might also operate in the human disease. It would be interesting to test whether mutations identified in this study do indeed accelerate tumour formation in a Brca2 deficient background. If this were the case, this would strengthen the argument for assessing whether the pathways that these genes modulate are also altered in human BRCA2 mutant breast cancers. Table S11 . CONTRA identified DNA target region alterations. Table S12 . CoNIFER identified DNA copy number alterations. Table S13 . Genes with copy number alteration detected by CONTRA and CoNIFER. Table 1 Figure and 
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